EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication

Teemu Maaniitty, Sarah Bär, Jeroen J. Bax, Juhani Knuuti, Antti Saraste

Circulation: Cardiovascular Imaging · 2026-04 · 19 (4)

DOI: 10.1161/circimaging.125.018840 ↗
AbstractBibliografische Angaben

Abstract

BACKGROUND: We hypothesized that quantification of coronary atherosclerotic plaque burden by artificial intelligence-guided quantitative computed tomography can identify patients who derive outcome benefit from lipid-lowering medication (LLM). METHODS: In this observational cohort study, consecutive symptomatic patients undergoing coronary computed tomography angiography for suspected coronary artery disease (CAD) were assessed for percent atheroma volume (PAV) by artificial intelligence-guided quantitative computed tomography. The use of LLM was assessed based on drug purchase registry data within 6 months after coronary computed tomography angiography. Patients were followed for the composite of death, myocardial infarction, and unstable angina for a median of 6.9 years. RESULTS: Among 2269 patients (median age, 63 years; 42% men), 1261 (56%) patients used LLM after coronary computed tomography angiography, and 255 (11%) experienced the composite end point during follow-up. The median PAV was 6.6% among users and 1.4% among nonusers of LLM ( P 5% (annual event rate, 2.62% versus 4.14%; adjusted P =0.002), even in the absence of obstructive CAD, but not among the 1359 patients with PAV ≤5% (annual event rate, 0.94% versus 0.65%; adjusted P =0.717). An adjusted Cox regression analysis, including interaction between PAV and LLM, suggested a PAV threshold between 4% and 10% for gaining prognostic benefit from LLM. CONCLUSIONS: In symptomatic patients with suspected CAD, LLM after coronary computed tomography angiography was associated with a lower rate of adverse events during long-term follow-up among those with PAV >5%, even in the absence of obstructive CAD. The quantification of coronary atherosclerotic plaque burden is a potential marker to guide preventive lipid-lowering therapy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →